BioSpace News Archive

Kato Pharmaceuticals, a privately-held clinical stage biopharmaceutical company, today announced that the FDA has approved the company’s investigational new drug (IND) application to conduct human studies using Resolv ER™ for the treatment of Vitreomacular Attachment (VMA).

The NuPET 66 will support research in a wide range of application areas including cancer, neurodegenerative diseases, diabetes, and genetic diseases such as cystic fibrosis, leukodystrophies, and polycystic kidney disease.

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue for the twelve months ended December 31, 2021 and provided a corporate update.

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

Roswell Biotechnologies, the molecular electronics company, announced today that Chief Science Officer Barry Merriman, Ph.D. will present a paper titled “A CMOS Molecular Electronics Chip for Single-Molecule Biosensing” at the prestigious International Solid-State Circuits Conference (ISSCC) on Feb. 22.

Ortho Clinical Diagnostics Holdings plc, one of the world’s largest pure-play in-vitro diagnostics companies, announced financial results for the fourth quarter and fiscal year ended January 2, 2022.

BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that it will provide a corporate update and report financial results for the fourth quarter and full year 2021 after the market closes on Wednesday, February 23, 2022.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 3, following release of its fourth quarter and full year 2021 financial results.

Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2021.